Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 0.47%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented both positive developments, such as exceeding revenue expectations and innovations in mRNA technologies, and significant challenges, like increased net loss and profitability concerns. The company's focus on growth and innovation is promising, but financial setbacks and potential geopolitical risks in China add complexity to the overall outlook.Company Guidance
During the Maravai LifeSciences Q1 2025 earnings call, the company reported $47 million in revenue, surpassing expectations and reflecting a base business growth of over $4 million from Q4 2024. Revenue was predominantly generated from the Nucleic Acid Production (NAP) segment at $29 million and the Biologic Safety Testing (BST) segment at $18 million. The call highlighted customer type revenue distribution: 29% biopharma, 28% life sciences and diagnostics, 6% academia, 7% CDMO, and 30% through distributors. Geographically, revenue was distributed as 62% from North America, 15% from EMEA, 15% from Asia Pacific, and 8% from China. Adjusted EBITDA was negative $11 million, with a GAAP net loss of $53 million. Despite challenges, the company reaffirmed its annual revenue guidance of $185 million to $205 million, highlighting strategic investments and a keen focus on expanding its market leadership in genomic medicines. The company also addressed potential impacts from tariffs, emphasizing its primarily U.S.-based supply chain and recent acquisitions to bolster vertical integration.Revenue Exceeds Expectations
Maravai LifeSciences reported $47 million in revenue for Q1 2025, surpassing the expected range and showing base business growth of more than $4 million from Q4 2024.
Nucleic Acid Production Segment Growth
The Nucleic Acid Production (NAP) segment reported $29 million in revenue for Q1, an increase from Q4 2024, highlighting growth in the segment.
Biologic Safety Testing Segment Stability
The Biologic Safety Testing (BST) segment reported $18 million in revenue for Q1, maintaining stability compared to Q1 2024.
Innovations in mRNA Technology
Launch of the Poly(A+) line to enhance mRNA performance, including a proprietary toolkit of Poly(A) tail modifications to protect and enhance mRNA molecules.
New License and Supply Agreements
Five new CleanCap license and supply agreements were signed, bringing the total to 48, indicating strong market adoption.
MRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.12 | $2.06 | -2.83% |
Mar 18, 2025 | $2.58 | $2.43 | -5.81% |
Nov 07, 2024 | $7.84 | $5.08 | -35.20% |
Aug 07, 2024 | $9.10 | $8.48 | -6.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Maravai Lifesciences Holdings (MRVI) report earnings?
Maravai Lifesciences Holdings (MRVI) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Maravai Lifesciences Holdings (MRVI) earnings time?
Maravai Lifesciences Holdings (MRVI) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRVI EPS forecast?
MRVI EPS forecast for the fiscal quarter 2025 (Q2) is -0.07.